Metformin is a diabetes drug commonly used to lower blood sugar levels. Metformin is popular with biohackers and longevity enthusiasts due to its believed anti-cancer properties and anti-aging effects. It is off patent and inexpensive.
TAME Trial: Targeting Aging with Metformin
TAME is the first FDA trial designed to measure the efficacy of a drug to delay the onset of age-related diseases. The hope is that the trial will pave the way for aging to be used as an indicator for longevity drugs in the future.
After years of struggling to finalize funding for the landmark $75 million dollar, a $40 million dollar donation by an anonymous donor has given TAME the go-ahead.
Aubrey de Grey, director of SENS Research Foundation, doesn't believe taking metformin will extend lifespan by much. But despite this, he has written that the TAME trial is a "genuinely good use of $75 million dollars". He argues first that TAME's establishment of aging as an indicator will make it easier for future FDA trials to test anti-aging interventions. Secondly, he believes that even a small positive statistical result will convince big pharma that it is possible in principle to modify aging in humans.